POIESIS Trial Explores Navtemadlin Plus Jakafi for Myelofibrosis
The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.
First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer
The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 DENALI clinical trial.
In Vivo CD19 CAR-T Leads to Remission in DLBCL Without Lymphodepletion
A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following novel in vivo CD19 CAR-T therapy.
First Patient Dosed in Trial of Ziftomenib for Advanced GIST
A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following progression on Gleevec.
First Patient Dosed in a Phase 1/2 Trial for Small Cell Lung Cancer
The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors.
First Patient Treated in Trial of PHST001 for Advanced Solid Tumors
Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.
Clinical Trial of NEO100 Recruiting Patients With Malignant Gliomas
A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.
Trial of SVV-001, Opdivo and Yervoy in Neuroendocrine Tumors Launching
A phase 1 clinical trial is open for enrollment to patients with high-grade neuroendocrine tumors.
First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.
BELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer
The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ovarian cancer has been launched.
FDA Approves Initiation of a New Trial in Recurrent Glioblastoma
The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a form of brain cancer.
Second-Line Tovecimig Elicits Responses in Biliary Tract Cancer
Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to COMPANION-002 study results.
Patient With Head and Neck Cancer Dosed in Trial of APR-1051
A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.
First Patient Dosed in Trial of [212Pb]VMT01 for Metastatic Melanoma
The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.
Progress Reported in Phase 1 Trial of CLD-101 for Recurrent Glioma
A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral doses.
First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small cell lung cancer.
First Patient Dosed in Phase 3 Trial of IBI354 for Ovarian Cancer
The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.
Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies.
First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
First Patent Dosed With Pocenbrodib in Trial for Metastatic Prostate Cancer
First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.
A Phase 1 Trial of Iadademstat Plus Vidaza Has Dosed a Patient With MDS
The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.
Breaking Down the CONVERGE Study of NBTXR3 in Stage 3 Unresectable NSCLC
The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.
First Patient Dosed in Study Assessing Immunotherapy in Metastatic Breast Cancer
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in metastatic breast cancer.
Phase 2 Study Assessing Alisertib in Metastatic Breast Cancer Subset Begins
A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus endocrine therapy.
First Patient Dosed in Trial of INT230-6 For Triple-Negative Breast Cancer
The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized triple-negative breast cancer.
First Patients Dosed in Three Trials Assessing Dato-DXd-Based Regimens in Lung Cancer
Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung cancer.
Phase 3 Trial Begins in mRNA-Based Therapy Plus Keytruda in Non-Small Cell Lung Cancer
This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.
First Patient With Ovarian Cancer Receives Peptide-Drug Conjugate in Study
This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types.
Patients Can Enroll in Pancreatic Cancer Vaccine Trial
Researchers are enrolling patients in a trial of ELI-00 7P — a vaccine to treat KRAS-mutant cancer.
IMNN-001 May Extend Survival in Advanced Gynecologic Cancers
Patients with advanced gynecologic cancer given IMNN-001 with presurgical chemotherapy tended to live nearly a year longer.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Image of Lungs.")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Image of tumor.")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Illustration of brain.")
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Image of woman holding her neck.")
